A detailed history of Cutler Group LP transactions in Replimune Group, Inc. stock. As of the latest transaction made, Cutler Group LP holds 700 shares of REPL stock, worth $10,451. This represents 0.0% of its overall portfolio holdings.

Number of Shares
700
Previous 300 133.33%
Holding current value
$10,451
Previous $2,000 150.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 19, 2024

BUY
$6.87 - $9.31 $2,748 - $3,724
400 Added 133.33%
700 $5,000
Q4 2023

Jan 18, 2024

BUY
$6.75 - $16.18 $2,025 - $4,854
300 New
300 $2,000

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $736M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.